Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass

Nature Medicine

Volumn 18, Issue 3, 2012, Pages 456-462

  Guan, Min ^a   Yao, Wei ^a   Liu, Ruiwu ^a   Lam, Kit S ^a   Nolta, Jan ^a   Jia, Junjing ^a   Panganiban, Brian ^b   Meng, Liping ^a   Zhou, Ping ^a   Shahnazari, Mohammad ^a   Ritchie, Robert O ^b   Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Lawrence Berkeley National Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; LIGAND; LLP2A ALENDRONATE CONJUGATE; OSTEOCALCIN; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BONE DEVELOPMENT; BONE MARROW; BONE MASS; BONE REGENERATION; BONE STRENGTH; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ESTROGEN DEFICIENCY; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; TRABECULAR BONE; XENOTRANSPLANTATION;

ALENDRONATE; ANIMALS; BONE MARROW CELLS; BONE REGENERATION; CELL DIFFERENTIATION; CELL MIGRATION ASSAYS; CELL PROLIFERATION; CELLS, CULTURED; DIPEPTIDES; HUMANS; IMMUNOCOMPETENCE; INTEGRIN ALPHA4BETA1; MESENCHYMAL STEM CELLS; MICE; OSTEOBLASTS; OSTEOGENESIS; PEPTIDOMIMETICS; PHENYLUREA COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 84858002781     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2665     Document Type: Article

References (40)

1. Stolzing, A., Jones, E., McGonagle, D. & Scutt, A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev. 129, 163-173 (2008).
2. Katsara, O. et al. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 20, 1549-1561 (2011).
3. Bonyadi, M. et al. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc. Natl. Acad. Sci. USA 100, 5840-5845 (2003).
4. Zhang, Y. et al. A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells. Biomaterials 31, 5312-5324 (2010).
5. Pedram, M.S. et al. Transplantation of a combination of autologous neural differentiated and undifferentiated mesenchymal stem cells into injured spinal cord of rats. Spinal Cord 48, 457-463 (2010).
6. Li, H., Yan, F., Lei, L., Li, Y. & Xiao, Y. Application of autologous cryopreserved bone marrow mesenchymal stem cells for periodontal regeneration in dogs. Cells Tissues Organs 190, 94-101 (2009).
7. Gutwald, R. et al. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep. Br. J. Oral Maxillofac. Surg. 48, 285-290 (2010).
8. Vertenten, G. et al. Evaluation of an injectable, photopolymerizable, and three-dimensional scaffold based on methacrylate-endcapped poly(D,L-lactide-co- epsilon-caprolactone) combined with autologous mesenchymal stem cells in a goat tibial unicortical defect model. Tissue Eng. Part A 15, 1501-1511 (2009).
9. Halleux, C., Sottile, V., Gasser, J.A. & Seuwen, K. Multi-lineage potential of human mesenchymal stem cells following clonal expansion. J. Musculoskelet. Neuronal Interact. 2, 71-76 (2001).
10. Longobardi, L. et al. Subcellular localization of IRS-1 in IGF-I-mediated chondrogenic proliferation, differentiation and hypertrophy of bone marrow mesenchymal stem cells. Growth Factors 27, 309-320 (2009).
11. Chapel, A. et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J. Gene Med. 5, 1028-1038 (2003).
12. Granero-Moltó, F. et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27, 1887-1898 (2009).
13. Gao, J., Dennis, J.E., Muzic, R.F., Lundberg, M. & Caplan, A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169, 12-20 (2001).
14. Meyerrose, T.E. et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 25, 220-227 (2007).
15. Cho, S.W. et al. Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice. Mol. Ther. 17, 1979-1987 (2009).
16. Jürg, A. Gasser, L.C.C., Kamibayashi, L.K. Intravenously administered mesenchymal OVX-induced bone loss in distribution of labeled MSCs. J. Bone Miner. Res. 14, 1 (1999).
17. Granero-Moltó, F. et al. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. Stem Cells 27, 1887-1898 (2009).
18. Owen, M. & Friedenstein, A.J. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found. Symp. 136, 42-60 (1988).
19. Bruder, S.P., Fink, D.J. & Caplan, A.I. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J. Cell. Biochem. 56, 283-294 (1994).
20. Muraglia, A., Cancedda, R. & Quarto, R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J. Cell Sci. 113, 1161-1166 (2000).
21. Adams, G.B. et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439, 599-603 (2006).
22. Chen, X.D., Dusevich, V., Feng, J.Q., Manolagas, S.C. & Jilka, R.L. Extracellular matrix made by bone marrow cells facilitates expansion of marrow-derived mesenchymal progenitor cells and prevents their differentiation into osteoblasts. J. Bone Miner. Res. 22, 1943-1956 (2007).
23. Grzesik, W.J. & Robey, P.G. Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 9, 487-496 (1994).
24. Vukicevic, S., Luyten, F.P., Kleinman, H.K. & Reddi, A.H. Differentiation of canalicular cell processes in bone cells by basement membrane matrix components: regulation by discrete domains of laminin. Cell 63, 437-445 (1990).
25. Gronthos, S., Simmons, P.J., Graves, S.E. & Robey, P.G. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 28, 174-181 (2001).
26. Gronthos, S., Stewart, K., Graves, S.E., Hay, S. & Simmons, P.J. Integrin expression and function on human osteoblast-like cells. J. Bone Miner. Res. 12, 1189-1197 (1997).
27. Brooke, G., Tong, H., Levesque, J.P. & Atkinson, K. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 17, 929-940 (2008).
28. Hamidouche, Z. et al. Priming integrin α5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc. Natl. Acad. Sci. USA 106, 18587-18591 (2009).
29. Mukherjee, S. et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118, 491-504 (2008).
30. Peng, L. et al. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2, 381-389 (2006).
31. Luo, J. et al. Rainbow beads: a color coding method to facilitate high-throughput screening and optimization of one-bead one-compound combinatorial libraries. J. Comb. Chem. 10, 599-604 (2008).
32. Yao, W. et al. Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice. PLoS ONE 5, e11410 (2010).
33. Cao, J., Venton, L., Sakata, T. & Halloran, B.P. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J. Bone Miner. Res. 18, 270-277 (2003).
34. Sato, M. et al. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143, 3230-3242 (2002).
35. Dao, M.A., Taylor, N. & Nolta, J.A. Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. Natl. Acad. Sci. USA 95, 13006-13011 (1998).
36. Seeman, E. Periosteal bone formation - a neglected determinant of bone strength. N. Engl. J. Med. 349, 320-323 (2003).
37. Kumar, S. & Ponnazhagan, S. Bone homing of mesenchymal stem cells by ectopic α4 integrin expression. FASEB J. 21, 3917-3927 (2007).
38. Parfitt, A.M. et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595-610 (1987).
39. Yao, W. et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58, 3485-3497 (2008).
40. Yao, W. et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J. Bone Miner. Res. 25, 190-199 (2010).